5 October 2017 - Most new cancer drugs are given to patients without any evidence that they extend or improve lives, an overview of data has concluded.

Only half show they have any real benefit, according to researchers who say regulators must make it harder for medicines to be approved. Other care for patients is being rationed to pay for drugs that are often useless, they add.

Regulatory approval, however, does not mean the NHS will pay for the drugs. Health chiefs will see the study as vindication of a tougher line which has seen them rejecting many new medicines as poor value for money.

Read The Times article